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Abstract Mitochondrial cytopathies are a heterogeneous
group of human disorders triggered by disturbed mitochon-
drial function. This can be due to primary mitochondrial
DNA mutations or nuclear defects affecting key components
of the mitochondrial machinery. Optic neuropathy is a fre-
quent disease manifestation and the degree of visual failure
can be profound, with a severe impact on the patient’s
quality of life. This review focuses on the major mitochon-
drial disorders exhibiting optic nerve involvement, either as
the defining clinical feature or as an additional component
of a more extensive phenotype. Over the past decade, sig-
nificant progress has been achieved in our basic understand-
ing of Leber hereditary optic neuropathy and autosomal-
dominant optic atrophy—the two classical paradigms for
these mitochondrial optic neuropathies. There are currently
limited treatments for these blinding ocular disorders and,
ultimately, the aim is to translate these major advances into
tangible benefits for patients and their families.
Keywords Dominant optic atrophy . Haplogroup .
Hereditary spastic paraplegia, Heteroplasmy . Idebenone .
Leber hereditary optic neuropathy .Mitochondrial DNA .
Mitofusin .Multiple sclerosis . Neuroprotection . Retinal
ganglion cell . Optic nerve .Mitochondrial cytopathies
Introduction
Mitochondria are found in all nucleated cells and reflecting
this ubiquitous presence, patients with mitochondrial cyto-
pathies often manifest a diverse combination of tissue and
organ involvement [1]. However, for reasons that still re-
main unclear, mitochondrial dysfunction has a marked pre-
dilection for the optic nerve, the latter being affected in
about half of all patients with confirmed mitochondrial
disease (Fig. 1). Irrespective of the molecular pathways
involved, remarkably, these mitochondrial optic neuropa-
thies all share the same pathological features—selective
degeneration of the retinal ganglion cell (RGC) layer, lead-
ing to progressive axonal loss and the onset of visual failure
[2]. In this review, recent advances in our understanding of
this important group of disorders are discussed, in addition
to promising therapeutic strategies.
Leber Hereditary Optic Neuropathy
Epidemiology
Leber hereditary optic neuropathy (LHON, OMIM 535000)
is named after Theodore Leber (1840–1917), a German
ophthalmologist who was the first to describe the key fea-
tures of this disorder [3]. LHON is the most common of the
primary mitochondrial DNA (mtDNA) disorders and the
minimum prevalence has been estimated at 1 in 31,000 in
the North of England (Fig. 1) [4]. Epidemiological studies
from the Netherlands and Finland have reported comparable
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figures of 1 in 39,000 and 1 in 50,000, respectively. In one
Australian study, 2% of individuals on the National Blind
Registry had optic atrophy secondary to LHON, highlighting
the significant socioeconomic burden of this inherited optic
nerve disorder. Three mtDNA point mutations—m.3460 G>
A, m.11778 G>A, and m.14484 T>C—account for the vast
majority (~ 90%) of LHON cases and, for this reason, they are
often referred to as “primary” (Table 1) [3, 5].
Clinical Manifestations
Typically, disease conversion in LHON is characterized by
acute or subacute central visual loss in one eye, followed 2
to 4 months later by the fellow eye [3, 5]. Unilateral optic
nerve involvement in LHON is exceptionally rare and an-
other underlying pathological process should be actively
excluded in these atypical cases. Bilateral simultaneous
onset probably occurs in about 25% of patients, although
it can be difficult for some individuals to accurately report
whether visual loss had been ongoing in one eye prior to the
fellow eye being affected. The peak age of onset is in the
second and third decades of life and it is unusual for symp-
toms to develop beyond 50 years of age.
The initial visual loss in LHON is severe and it usually
plateaus over the next 6 months, with most patients achiev-
ing visual acuities of 20/200 or worse [3, 5]. There is an
associated dense central or centrocecal scotoma and color
vision is significantly impaired. The pupillary light reflexes
are relatively preserved and this rather surprising feature has
recently been ascribed to a special class of melanopsin-
containing RGCs that are more resistant to the mtDNA
LHON mutations [6••]. In the acute phase, classically, there
is optic disc hyperemia, peripapillary telangiectatic vessels,
vascular tortuosity, and retinal nerve fiber layer (RNFL)
edema secondary to axonal stasis. In a proportion (20% to
40%) of LHON carriers undergoing disease conversion, the
optic discs can look entirely normal, followed 6 weeks later
by the development of neuroretinal rim pallor [5]. Patholog-
ical cupping of the optic disc is also a recognized feature of
longstanding LHON cases, reflecting the ongoing loss of
RGC axons in the chronic phase of the disease. The overall
prognosis in LHON is poor, even among patients harboring
the m.14484 T>C mutation, which carries the best chance
for partial visual recovery [5]. If it occurs, a slow improve-
ment in visual parameters can be expected within the first
year, although more delayed visual recovery has been
reported.
Syndromal LHON Phenotypes
LHON is typically a monosymptomatic disease but addi-
tional features such as cardiac conduction defects, peripheral
neuropathy, dystonia, and myopathy have been reported as
occurring more frequently among LHON carriers. In partic-
ular, there is a well-reported association between the three
primary mtDNA LHON mutations and a multiple sclerosis–
like illness, especially among female carriers. Rarer patho-
genic mtDNA variants have been linked with more atypical
“LHON +” syndromes, where the optic neuropathy segre-
gated with prominent neurological features including spastic
dystonia, ataxia, juvenile-onset encephalopathy, and psychi-
atric disturbances [2].
Figure 1 Mitochondrial
disease in the North of England.
(Adapted from Yu-Wai-Man et
al. [2] and Schaefer et al. [50])
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Disease Modifiers
LHON is characterized by incomplete penetrance and a
marked sex bias, with only about 50% of male carriers and
about 10% of female carriers losing vision during their life-
time. The pathological consequences of the mtDNA LHON
mutations are clearly being influenced by other disease modi-
fiers, and these can be classified into four main groups: 1) the
mitochondrial genetic background, 2) nuclear susceptibility
genes, 3) hormonal differences, and 4) environmental triggers.
As mitochondria have a high copy number genome,
LHON carriers can be homoplasmic (100% mutant) for the
mtDNA mutation, or heteroplasmic with a combination of
both the wild-type and mutant mtDNA species. Although
the risk of visual loss is minimal at heteroplasmy levels
below 60%, this observation cannot account for the bulk
of unaffected LHON carriers, most of whom are homoplas-
mic mutant and therefore beyond this biochemical threshold
[7]. MtDNA is highly polymorphic and during human evo-
lution, ancient mtDNA variants have clustered together in
specific combinations known as haplogroups. As mtDNA
haplogroups influence mitochondrial oxidative phosphory-
lation, these more subtle variations could magnify or lessen
the impact of the LHON mutation on RGC survival. In a
large study involving 159 Caucasian LHON pedigrees, hap-
logroup J was associated with a significantly increased risk
of visual loss among m.11778 G>A and m.14484 T>C
carriers, whereas m.3460 G>A carriers were more likely
to become affected on a haplogroup K background [8].
Haplogroup H had a protective effect but only among indi-
viduals harboring the m.11778 G>A mutation. Haplogroup
associations have been reported in other ethnic groups,
supporting a contributory role for the mtDNA background
in influencing LHON penetrance [9].
The predilection for males to lose vision in LHON cannot
be explained by mitochondrial genetics and a visual loss
susceptibility gene on the X chromosome has long been
suspected, the so-called two-locus disease model [10]. Al-
though such an X-linked disease modifier gene has yet to be
formally identified, three independent linkage studies have
revealed overlapping candidate regions, providing strong ev-
idence for its existence [11–13]. Another obvious factor to
account for the observed male bias in LHON is a protective
influence conferred by female sex hormones. This hypothesis
was recently investigated using LHON cybrid cell lines, and
interestingly, treatment with 17β-estradiol resulted in reduced
reactive oxygen species (ROS) levels, increased activity of the
antioxidant enzyme superoxide dismutase, and more efficient
mitochondrial biogenesis [14•].
Various environmental factors have been implicated in
precipitating visual loss among LHON carriers including
head trauma, industrial toxins, and drugs with mitochondrial
toxic effects [15]. The evidence for these environmental
triggers is largely anecdotal, but a recent multicenter study
of 125 LHON pedigrees has provided convincing evidence
for an increased risk of visual failure among smokers, and to
a lesser extent, heavy drinkers [16•].
Mitochondrial Encephalomyopathies
The mitochondrial encephalomyopathies encompass sev-
eral distinct phenotypes such as mitochondrial encepha-
lomyopathy, lactic acidosis, and stroke-like episodes
(MELAS), myoclonic epilepsy and ragged-red fibers
(MERRF), maternally inherited Leigh syndrome (MILS),
mitochondrial neurogastrointestinal encephalomyopathy
(MNGIE), and the Kearns-Sayre syndrome (KSS) [1,
Table 1 mtDNA variants associated with LHON
Mitochondrial
gene
Nucleotide change
Common variants
(~ 90%)
MTND1 m.3460 G>Aa
MTND4 m.11778 G>Aa
MTND6 m.14484 T>Ca
Rare variants
(~ 10%)
MTND1 m.3376 G>A, m.3635 G>Aa,
m.3697 G>A, m.3700 G>A,
m.3733 G>Aa, m.4025 C>T,
m.4160 T>C, m.4171 C>Aa
MTND2 m.4640 C>A, m.5244 G>A
MTND3 m.10237 T>C
MTND4 m.11696 G>A, m.11253 T>C
MTND4L m.10663 T>Ca
MTND5 m.12811 T>C, m.12848 C>T,
m.13637 A>G, m.13730 G>A
MTND6 m.14325 T>C, m.14568 C>T,
m.14459 G>Aa, m.14729 G>A,
m.14482 C>Aa, m.14482 C>
Ga,
m.14495 A>Ga, m.14498 C>T,
m.14568 C>Ta, m.14596 A>T
MTATP6 m.9101 T>C
MTCO3 m.9804 G>A
MTCYB m.14831 G>A
Over 70% of LHON carriers harbor the m.11778 G>A mutation, but as
a result of a founder event, the m.14484 T>C mutation has been
identified in nearly 90% of all affected patients of French Canadian
descent [3, 5]. In most laboratories worldwide, the diagnostic protocol
involves screening for the three “primary” LHON mutations in the first
instance. As full mitochondrial genome sequencing remains time con-
suming and expensive, this is only indicated if the initial LHON screen
is negative and there is a strong clinical suspicion
a These mtDNAvariants are definitely pathogenic. They have been iden-
tified in two or more independent LHON pedigrees, showing segregation
with affected disease status. The remaining putative LHON mutations
have been found in singleton cases or in a single family, and additional
evidence is required before pathogenicity can be irrefutably ascribed
LHON Leber hereditary optic neuropathy; mtDNA mitochondrial DNA
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17]. Although variable and not a disease-defining fea-
ture, the occurrence of optic atrophy is well described
in this group of patients, exacerbating the already con-
siderable disease burden [18]. Additional studies are
required to determine the true prevalence of both clini-
cal and subclinical optic neuropathy in these mitochon-
drial encephalomyopathies, and whether specific mtDNA
mutations or phenotypes are linked with an increased
risk of optic nerve involvement.
Nuclear Mitochondrial Disorders
Autosomal-Dominant Optic Atrophy
Epidemiology
Frederick Batten (1865–1918), a pediatric neurologist, is
credited with the first report of autosomal-dominant optic
atrophy (DOA) in one British family. The characteristic
features were described in greater detail by Poul Kjer in a
large cohort of Danish families, establishing DOA as a
distinct clinical entity from LHON [3]. The prevalence of
DOA was estimated at 1 in 35,000 in the North of England
(Fig. 1), but additional families have since been identified
and the true figure is likely to be much higher (Yu-Wai-Man,
Unpublished data).
Disease Genes and Candidate Loci
Between 50% and 60% of families with DOA harbor path-
ogenic mutations in OPA1, which codes for a mitochondrial
inner membrane protein (Table 2) [3, 5]. OPA1 is highly
polymorphic and over 200 pathogenic variants have been
identified, clustering in the GTPase region and the dynamic
central domain. To minimize cost, OPA1 is routinely se-
quenced using polymerase chain reaction–based methods,
which will not detect exonic deletions or duplications. These
large-scale rearrangements have been identified in 10% to
20% of OPA1-negative families, and these additional mo-
lecular studies, although not yet widely available, are rec-
ommended for probands with a clear-cut DOA phenotype
and a strong family history [2].
Mutations in OPA3 were first described in Iraqi-Jewish
families with autosomal-recessive type III 3-methylglutaconic
aciduria (Costeff syndrome), a progressive neurodegenerative
disorder with early-onset optic atrophy, hypotonia, ataxia,
extrapyramidal dysfunction, and cognitive decline [19]. Het-
erozygous OPA3mutations were subsequently reported in two
French families with a dominantly inherited form of optic
atrophy associated with premature cataract formation
(ADOAC) [20]. Similar to OPA1, OPA3 has a mitochondrial-
targeting domain and it was initially considered to be a mito-
chondrial inner membrane protein. However, a recent study
has suggested instead thatOPA3 localizes to the mitochondrial
outer membrane, with its C-terminus facing the cytosol [21].
The causative genetic defects in the remaining families with
DOA have not yet been identified, although a number of
candidate loci have been reported (Table 2).
Visual Function and Disease Progression
Visual loss in DOA is bilateral and symmetrical with the
majority patients reporting subnormal vision from early child-
hood. There is a wide intra- and inter-familial variability in
disease severity, with visual acuities ranging from 20/20 to the
detection of hand movement [2, 3]. Individuals with visual
acuities of 20/30 or better are frequently asymptomatic and
they are only identified as having features of a bilateral optic
neuropathy at the time of contact tracing. On long-term
follow-up, visual function was observed to deteriorate in
50% to 75% of patients with DOA but the rate of progression
was highly variable, making genetic counseling difficult [2,
3]. Although a milder optic nerve disease compared with
LHON, DOA still results in significant visual impairment with
nearly half of all patients eventually registered blind.
As in LHON, the primary site of pathology in DOA is the
papillomacular bundle and central, centrocecal, and
Table 2 Nuclear mitochondrial disorders with prominent optic nerve involvement
Inheritance Locus Gene OMIM Phenotypes
Dominant 1p36.2 MFN2 601152 Hereditary motor and sensory neuropathy type 6 (HMSN-6, CMT2A)
3q28–q29 OPA1 165500 Isolated optic atrophy and syndromal dominant optic atrophy (DOA+)
19q13.2–q13.3 OPA3 165300 Autosomal-dominant optic atrophy and early-onset cataracts (ADOAC)
Recessive 9q13–q21.1 FXN 229300 Friedreich’s ataxia (FRDA)
11q14.1–q21 TMEM126A 612989 Optic atrophy ± auditory neuropathy
16q24.3 SPG7 607259 Hereditary spastic paraplegia type 7 (HSP-7)
19q13.2–q13.3 OPA3 258501 Type III 3-methylglutaconic aciduria (Costeff syndrome)
(Adapted from Yu-Wai-Man et al. [2, 5])
Curr Neurol Neurosci Rep (2012) 12:308–317 311
paracentral scotomas are the most common visual field
defects. The degree of dyschromatopsia is commensurate
with the level of vision and pure tritanopia, once considered
a pathognomonic feature of DOA, is only rarely seen. Histo-
pathological studies of a postmortem eye retrieved from one
patient showed relative preservation of melanopsin-
containing RGCs, accounting for the lack of an afferent pu-
pillary defect in DOA—another peculiarity shared with
LHON [6••]. The optic nerve head in DOA can look diffusely
pale or it can have a characteristic temporal wedge, especially
in patients with early disease where RGC loss remains mostly
localized to the papillomacular bundle [2, 3].
The Expanding Phenotypic Spectrum
Up to 20% of patients harboringOPA1mutations will develop
a syndromal form of the disease (DOA+) marked by signifi-
cant neurological complications [22•]. The most common
extraocular feature observed in this group is sensorineural
hearing loss, which usually manifests itself in the second
and third decades of life after visual failure has become
apparent. A proportion of OPA1 carriers will progress to a
more debilitated state with variable combinations of ataxia,
peripheral neuropathy, myopathy, and progressive external
ophthalmoplegia in later life. From a mechanistic perspective,
it is also revealing that some patients with DOA+ can present
with clinical features indistinguishable from other neurode-
generative disorders such as multiple sclerosis, hereditary
spastic paraplegia (HSP), and the inherited spinocerebellar
degenerations. The phenotypic spectrum of OPA1 disease is
likely to expand even further with greater clinical awareness
and easier access to molecular genetic testing.
Other Nuclear Mitochondrial Optic Neuropathies
The nuclear defects underlying several common neuromus-
cular disorders have been clarified. A remarkable element
has been the increasing realization that mitochondrial dys-
function plays a central role in the pathophysiology of
disease groups as diverse as Charcot-Marie-Tooth (CMT)
disease, HSP, and the inherited spinocerebellar ataxias—
reflecting to a certain extent the broader phenotypic spec-
trum recently described for OPA1 disease [2]. Mutations in
MFN2, which codes for a critical mitochondrial outer mem-
brane protein, have been identified in patients with heredi-
tary motor and sensory neuropathy type 6 (HMSN-6), an
autosomal-dominant axonal CMT subtype (Table 2) [23].
Affected individuals develop an early-onset peripheral neu-
ropathy with a progressive bilateral optic atrophy in later
childhood. Optic neuropathy also features prominently in
Friedreich ataxia and HSP type 7 (HSP-7), caused by nu-
clear mutations in FXN and SPG7, respectively [2]. Frataxin
is essential for the assembly of the iron-sulfur clusters
embedded within the mitochondrial respiratory chain com-
plexes, whereas paraplegin is a key mitochondrial protease
involved in the proteolytic processing of OPA1 [24, 25]. All
these disease pathways are likely interrelated, and distur-
bance in one element will set into motion a vicious cycle,
which eventually disturbs mitochondrial homeostasis trig-
gering neuronal cell loss. As the molecular basis of other
inherited human diseases is uncovered, it will be interesting
to note whether optic atrophy is present in those cases where
the genetic defect is ultimately revealed to affect mitochon-
drial function. A recent example is the identification of
TMEM126A mutations among patients with autosomal-
recessive optic atrophy, with or without an associated audi-
tory neuropathy [26]. Although its exact functions still re-
main to be determined, fascinatingly, TMEM126A is a
mitochondrial transmembrane protein present at high levels
within the RGC layer and the optic nerve head [26].
Mechanisms Contributing to RGC Loss
The final pathological outcome in mitochondrial optic neu-
ropathies is apoptotic RGC loss and several disease path-
ways can contribute to this irreversible process. Although a
greater emphasis has been placed on the experimental data
obtained for LHON and DOA, similar mechanisms have
also been shown to operate in other mitochondrial
cytopathies.
Bioenergetic Failure
Mitochondria are the cell’s powerhouses providing most of its
adenosine triphosphate (ATP) requirements through the tight
control of mitochondrial respiratory chain activity. All three
primary LHON mutations—m.3460 G>A, m.11778 G>A,
andm.14484 T>C—disrupt key polypeptide subunits of com-
plex I. Similarly, OPA1 mutations have a detrimental impact
on mitochondrial oxidative output by impairing the assembly
and stability of the respiratory chain complexes [27]. Most
studies, based on in vitro or in vivo assays, indicate a signif-
icant impairment in complex I activity, leading to a reduction
in mitochondrial membrane potential and overall ATP synthe-
sis (reviewed in [5] and [15]). Although this bioenergetic
deficit is bound to impact negatively on RGCs, by itself, this
cannot account for their selective vulnerability. Photorecep-
tors, for example, have a much higher energetic demand and
outer retinal function is usually preserved in both LHON and
DOA.
ROS and Excitotoxicity
The disrupted flow of high-energy electrons along the res-
piratory chain leads to free radical production and increased
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ROS levels have been consistently observed in transmito-
chondrial LHON cybrids (reviewed in [5] and [15]). The
efficient reuptake of glutamate is also disrupted in these
cellular models due to the downregulation of excitatory
amino acid transporter (EAAT1) activity. A drosophila
Opa1 (dOpa1) model has recently been established and
homozygous mutant flies developed a rough and glossy
eye phenotype due to the loss of hexagonal lattice cells,
with decreased lens and pigment deposition. This genetical-
ly engineered dOpa1 mutation led to a dramatic increase in
ROS levels, which could be partially rescued with dietary
antioxidant supplementation or overexpression of SOD1
[28]. Heterozygous adult flies were phenotypically normal
but similar to the homozygotes, ROS levels were elevated
with clear evidence of cellular oxidative stress. Increased
ROS levels and glutamate excitotoxicity clearly represent a
toxic combination, sufficiently potent to initiate the apopto-
tic cascade.
Disturbed Calcium Handling
Besides its localization to the mitochondrial outer mem-
brane, MFN2 is also associated with the endoplasmic retic-
ulum (ER), resulting in a close communication between the
mitochondrial and ER membranes [29••, 30]. When the
MFN2 protein is disrupted or absent, as in CMT-2A this
tethering effect is lost with dramatic consequences on cel-
lular calcium homeostasis. The ER and mitochondrial net-
work are important calcium stores and the dynamic flux
between these two compartments buffers against cytosolic
calcium spikes, which can sensitize the cell to various pro-
apoptotic signals such as glutamate [29••, 30]. Mirroring the
pathomechanism of MFN2 mutations, mtDNA point muta-
tions involving complex I and complex IV subunits have
also been directly linked with disturbed calcium handling in
neuronal populations [31]. Although speculative, it is likely
that a similar process is operating in LHON and DOA,
contributing to RGC dysfunction and ultimately disease
conversion among at-risk mutational carriers [32]. The
emerging links between calcium homeostasis and mitochon-
drial dysfunction are an exciting new development, high-
lighting potential disease pathways amenable to therapeutic
intervention.
Mitochondrial Network Dynamics
Cytochrome c is a powerful pro-apoptotic mediator and as a
protective mechanism, high concentrations of these mole-
cules are carefully sequestered within the mitochondrial
cristae. Irrespective of the mtDNA mutation involved, the
dissipation of the mitochondrial membrane potential
accelerates the cytosolic release of these cytochrome c mol-
ecules, precipitating an irreversible commitment toward
programmed cell death [33]. The identification of OPA1
and MFN2 mutations in DOA and CMT-2A has provided
further insights into this key disease mechanism. OPA1
ensures the integrity of the mitochondrial cristae’s tight
junctions, preventing cytochrome c from leaching out into
the cytosolic space. In addition, OPA1 and MFN2 both
belong to the dynamin superfamily of mechanoenzymes,
sharing considerable structural similarities, including a high-
ly conserved catalytic GTPase domain [24]. These two
proteins have important pro-fusional properties and by
working closely together, they maintain a highly-
interconnected mitochondrial network throughout the cell’s
structure [24, 33]. Unsurprisingly, the pathological hallmark
of OPA1- and MFN2-mutant fibroblasts is mitochondrial
network fragmentation, which not only impairs mitochon-
drial oxidative phosphorylation, but also leads to the uncon-
trolled release of calcium and cytochrome c into an already
compromised cellular environment [27, 34, 35••].
Somatic mtDNA Defects
Pathological levels of cytochrome c oxidase–negative fibers
have been identified in skeletal muscle biopsies from
patients with DOA+ [35••, 36••]. The underlying biochem-
ical defect in these muscle fibers is secondary to the accu-
mulation of high levels of somatic mtDNA deletions, which
have clonally expanded during the patient’s lifetime, partly
accounting for the delayed onset of these extraocular fea-
tures [37••]. Intriguingly, the risk of developing DOA+ is
three times higher with missense mutations targeting the
functional GTPase domain, consistent with a dominant-
negative mutational effect [22•]. OPA1 is clearly involved
in preserving the integrity of the mitochondrial genome and
recent studies have provided some tantalizing insights into
the mechanisms that contribute to mtDNA instability [38],
[39••, 40••]. OPA1 is thought to anchor the mtDNA repli-
cative machinery, known as nucleoids, to the mitochondrial
inner membrane and a dominant-negative mutation could
plausibly upset this delicate balance, leading to mtDNA
deletion formation [40••]. Why is this relevant to our under-
standing of RGC loss? Patients with DOA+ have worse
visual acuities and significantly thinner RNFL thickness
compared with those who only develop isolated optic atro-
phy [41]. The accumulation of these somatic mtDNA dele-
tions is therefore clearly having an incremental effect on the
other deleterious consequences linked to OPA1 mutations.
Why Are RGCs Selectively Vulnerable?
One factor that could explain this tissue-specific vulnerabil-
ity is the rather unusual anatomical peculiarity encountered
at the lamina cribrosa, where RGC axons first acquire their
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myelin sheaths. This transition is marked by a sharp differ-
ential gradient, with a much higher density of mitochondria
and voltage-gated sodium channels in the pre-laminar un-
myelinated segment of the optic nerve [42, 43]. These
physiological adaptations facilitate the efficient propagation
of action potentials in the absence of an insulating myelin
covering. The pre-laminar region therefore represents a
weak link, significantly more exposed to the disadvanta-
geous consequences of, even subtle, mitochondrial bio-
chemical defects.
Histopathological studies of optic nerves retrieved from
two patients with LHON, one harboring the m.3460 G>A
mutation and the other the m.11778 G>A mutation, have
revealed some interesting observations on the susceptibility
of specific RGC populations (reviewed in [2] and [15]). A
prominent loss of smaller-caliber axons was observed,
corresponding to the parvocellular RGC population, where-
as the larger-caliber magnocellular RGCs were relatively
preserved. These ultrastructural findings were subsequently
confirmed with higher-resolution transmission electron mi-
croscopy. Parvocellular RGCs are a major component of the
papillomacular bundle and this greater vulnerability to im-
paired mitochondrial oxidative phosphorylation could be
related to their relatively smaller cross-sectional areas, the
latter further exacerbating axonal stasis in conditions of
sustained metabolic stress.
The maintenance of a higher mitochondrial concentration
in the pre-laminar region also highlights the central role
played by the cytoskeleton, especially the microtubule net-
work, in channeling mitochondria to their appropriate cel-
lular locations. Axonal transport in highly specialized
neuronal populations such as RGCs is critically dependent
on these mitochondrial-cytoskeletal interactions (reviewed
in [2] and [15]). These can be adversely affected either by an
underlying mitochondrial respiratory chain defect, or by a
primary disturbance in microtubule assembly—the patho-
logical hallmark of the HSP group of disorders [2]. Optic
atrophy is well described in HSP-7 and it is likely that optic
nerve involvement remains an under-reported feature in
other HSP genetic subtypes.
Therapeutic Interventions
Visual Rehabilitation
The majority of patients with mitochondrial optic neuropa-
thies are severely visually impaired and the sudden onset of
visual loss in otherwise healthy individuals carries a signif-
icant psychological and socioeconomic burden. Therefore,
clinicians have an important role to play in facilitating
access to rehabilitative services such as low visual aids
and occupational therapy.
Clinical Surveillance
It is essential to screen for associated systemic complica-
tions, such as diabetes and cardiomyopathy, among patients
with mitochondrial cytopathies. The development of diabet-
ic peripheral neuropathy and cardiac-related exertional dys-
pnea can further compound the physical difficulties faced by
patients with poor vision, and they should be aggressively
managed as part of a multidisciplinary team. As a general
health measure, patients with mitochondrial disease should
be advised not to smoke and to moderate their alcohol
intake. Furthermore, in LHON, smoking, and to a lesser
extent excessive binge drinking, have been linked with an
increased risk of visual loss [16•].
Pharmacological Agents
Various pharmacological agents with putative neuroprotec-
tive properties have been used to mitigate the deleterious
consequences of mitochondrial dysfunction and to prevent
further RGC loss (reviewed in [44••]). The most promising
agent to date is idebenone (2,3-dimethoxy-5-methyl-6-[10-
hydroxydecyl]-1,4-benzoquinone), a short-chain synthetic
benzoquinone analogue, which promotes mitochondrial
ATP synthesis in addition to having antioxidant properties.
Coenzyme Q10 (CoQ10) is a longer-chain quinone analogue
and based on limited evidence, CoQ10 supplementation is
often used to treat patients with mitochondrial cytopathies.
Idebenone is thought to have some advantageous properties
over CoQ10, both in terms of its bioavailability and its mode
of action. Unlike CoQ10, idebenone is able to bypass com-
plex I inhibition by shuttling electrons directly from the
cytosol to complex III, thereby restoring ATP production
and decreasing lactate levels [45].
The results of a multicenter randomized placebo-
controlled trial (RHODOS [Rescue of Hereditary Optic
Disease Outpatient Study]) of idebenone in LHON have
recently been released. Idebenone was well tolerated at a
dose of 900 mg per day and no adverse drug-related events
were reported. The visual outcome data indicate that
patients with discordant visual acuities (LogMAR>0.2),
and thus at highest risk of further deterioration in the least
affected eye, were more likely to benefit from treatment
with idebenone [44••]. The findings from the RHODOS trial
are promising and for the first time, they offer the hope of
preserving vision for affected LHON carriers who are still at
an early stage of the disease process.
Looking into the Future: Gene Therapy
Gene therapy for primary mitochondrial cytopathies poses
several discrete challenges; the mitochondrial inner mem-
brane is a relatively impermeable membrane that needs to be
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bypassed, and a highly efficient vector is needed to
transfect a sufficient number of mitochondria per cell
to achieve the desired effect. A possible solution is to
bypass the mitochondrial genome using an allotopic
approach. Instead, the gene of interest is transfected into
the nuclear genome and the protein product is engi-
neered with a specific targeting sequence that facilitates
its uptake into the mitochondrial compartment, thereby
compensating for the mtDNA mutation. Proof of prin-
ciple has been demonstrated in experimental LHON
models where adeno-associated virus vectors have been
used to successfully transfect cells with a replacement
wild-type mtDNA allele or neuroprotective genes such
as SOD2 [46–48]. These results are encouraging and
allotopic rescue could be easily applied to the RGC
layer which is easily accessible. However, key issues
of safety and efficacy need to be further addressed
before their application to human clinical trials can be
advocated [2].
Preventing Disease Transmission
Several strategies are currently being explored to prevent the
transmission of pathogenic mitochondrial and nuclear muta-
tions among women of child-bearing age. The difficult
technical and ethical issues raised by preimplantation genet-
ic testing and new in vitro fertilization techniques such as
pronuclear transfer are outside the scope of this review, and
these have been detailed elsewhere [2, 49].
Conclusions
A number of recurring disease mechanisms have been iden-
tified that contribute to RGC loss in mitochondrial optic
neuropathies. These provide a unique opportunity for tar-
geted therapeutic interventions aimed not only at improving
visual function, but also the neurological deficits seen in the
more severe mitochondrial cytopathies. However, despite
these major advances, the risk factors underpinning the
selective vulnerability of RGCs have yet to be clarified.
Research in this area has been severely limited by the lack
of diseased human optic nerves but hopefully, with the
development of faithful animal models and more advanced
biotechnological tools, we will soon be in a position to
disentangle these fundamental research questions both at
the structural and molecular levels.
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